Skip to main content
. Author manuscript; available in PMC: 2011 Jul 17.
Published in final edited form as: Am J Surg Pathol. 2006 Jul;30(7):802–810. doi: 10.1097/01.pas.0000209855.28282.ce

TABLE 1.

PD-1 Immunostaining in Lymphoproliferative Disorders

PD-1 Immunostaining
B-cell LPDs 0/42*
 B-LL/LL 0/3
 CLL 0/4
 MCL 0/4
 FL 0/6
 MZL 0/3
 HCL 0/3
 DLBCL 0/6
 BL 0/7
 LPL 0/3
 MM 0/3
Hodgkin lymphoma 0/25
 Classical 0/11
 Nodular lymphocyte-predominant 0/14†
T cell LPDs 23/60
 T-LL/LL 0/5
 T-PLL 0/3
 AIL 23/23
 PTCL, unspecified 0/14
 ALCL 0/12
 ATLL 0/3
*

Number of immunoreactive cases/total number of cases.

†

PD-1-positive T cells form rosettes around neoplastic L&H cells in 14/14 cases.

B-LL/LL indicates precursor B-cell lymphoblastic lymphoma/lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; MCL, mantle cell lymphoma; FL, follicular lymphoma; MZL, marginal zone lymphoma; HCL, hairy cell leukemia; DLBCL, diffuse large B-cell lymphoma; BL, Burkitt lymphoma; LPL, lympho-plasmacytic lymphoma; MM, multiple myeloma; T-LL/L, precursor T-lympho-blastic leukemia/lymphoblastic lymphoma; T-PLL, T-cell prolymphocytic leukemia; AIL, angioimmunoblastic lymphoma; PTCL, peripheral T-cell lymphoma, unspecified; ALCL, anaplastic large cell lymphoma; ATLL, adult T-cell leukemia/lymphoma.